There are 46 million Americans with Alzheimer's disease in their brain right now, but no symptoms. --Richard Isaacson
I have two blogs. More like one and a half. The other one is sort of a repository for information. I don’t pay for that one and at times I think it may have run its course but then I think of something else I want to park over there. The name of it is Alzheimer’s Disease: The Brand and there is plenty of value over there but also plenty I have learned that I replicate over here.
For example, you really need to do your homework. The hard tedious bits. I long advocated the work of Dr. Dale Bredesen and I am not exactly recanting but it never occurred to me to look at the data he cited from the literature in support of the claims made in his writings.The person that dug into the findings and the data in the resources cited by Dr Bredesen was Dr Peter Attia. I have listened to his podcast and read his posts for years. He has evolved into more of a pay to play model for some of his podcast show notes and communications so I was unable to locate the conclusion. Regardless I still follow many of the earlier recommendations simply because they still make sense.
An article in The Washington Post, Atypical forms of dementia are being diagnosed more often in people in their 50s and 60s caught my attention. All gloom and doom and no grounding in the granularity needed to describe the known heterogeneity of Alzheimer’s Disease.
My dad had Alzheimer’s disease likely because of head trauma in a car accident years before we were able to make the probable diagnosis. So with uncertainty regarding any long term benefits from the lifestyle recommendations in the literature I decided to focus my attention on longevity and prevention--the focus of The Drive.
Here is a direct link to the podcast Alzheimer’s disease prevention--patient and doctor perspectives
And it sounds like what you're saying is Alzheimer's is not really one disease. it's an umbrella term that encompasses many different diseases of the brain that have some common features in the way that all cancers have some common features, cells don't respond to normal signaling, but there's this notion that someone could have a form of Alzheimer's that largely spares the frontal cortex and therefore preserve some higher order functioning versus another person that has.--Peter Attia
Here is an additional resource--an article authored by both Peter and Richard (as well as others). Click on title for full article.
Multidomain intervention for Alzheimer's disease (AD) risk reduction is an emerging therapeutic paradigm.
Patients were prescribed individually tailored interventions (education/pharmacologic/nonpharmacologic) and rated on compliance. Normal cognition/subjective cognitive decline/preclinical AD was classified as Prevention. Mild cognitive impairment due to AD/mild-AD was classified as Early Treatment. Change from baseline to 18 months on the modified Alzheimer's Prevention Cognitive Composite (primary outcome) was compared against matched historical control cohorts. Cognitive aging composite (CogAging), AD/cardiovascular risk scales, and serum biomarkers were secondary outcomes.
One hundred seventy-four were assigned interventions (age 25–86). Higher-compliance Prevention improved more than both historical cohorts (P = .0012, P < .0001). Lower-compliance Prevention also improved more than both historical cohorts (P = .0088, P < .0055). Higher-compliance Early Treatment improved more than lower compliance (P = .0007). Higher-compliance Early Treatment improved more than historical cohorts (P < .0001, P = .0428). Lower-compliance Early Treatment did not differ (P = .9820, P = .1115). Similar effects occurred for CogAging. AD/cardiovascular risk scales and serum biomarkers improved.
Individualized multidomain interventions may improve cognition and reduce AD/cardiovascular risk scores in patients at-risk for AD dementia.
I will continue to share information, preferentially in this blog, due to the limits of a free Weebly account.